Earnings Call Summary | Establishment Labs(ESTA.US) Q2 2024 Earnings Conference
Earnings Call Summary | Establishment Labs(ESTA.US) Q2 2024 Earnings Conference
The following is a summary of the Establishment Labs Holdings Inc. (ESTA) Q2 2024 Earnings Call Transcript:
以下是Establishment Labs Holdings Inc. (ESTA)二零二四年第二季度業績會議通話記錄摘要：
Financial Performance:
金融業績：
Establishment Labs reported a Q2 2024 revenue of $44.1 million.
Sequential revenue growth was 18.7%, indicating a stabilization and growth return in current markets.
Adjusted EBITDA loss for Q2 was approximately $4 million, showing improvement from last year.
Gross profit for Q2 was $28.9 million, or 65.6% of revenue, attributed to an increase in average selling prices.
Net loss from operations for Q2 was $9.3 million, showing an improvement from the previous year.
Establishment Labs報告二零二四年第二季度營業收入4410萬美元。
環比增長18.7%，表明當前市場正在穩定增長。
二零二四年第二季度調整後的EBITDA虧損約爲400萬美元，相比去年有所改善。
二零二四年第二季度毛利潤爲2890萬美元，佔營業收入的65.6%，歸因於平均銷售價格的增加。
二零二四年第二季度業務虧損930萬美元，較去年有所改善。
Business Progress:
業務進展：
Establishment Labs is preparing for the U.S. launch of Motiva implants, anticipating FDA approval.
Significant interest and preparations underway for the U.S. market with enhanced commercial operations and team build-outs.
Continued traction in international markets, particularly with the Mia Femtech product expanding to new regions.
Active efforts to manage the softer demand in Brazil through various strategic initiatives.
Establishment Labs正在爲Motiva植入物的美國上市做準備，預計FDA會批准。
在加強商業運營和團隊建設方面，已經有了顯著的興趣和準備。
國際市場的持續發展，特別是Mia Femtech產品在新區域的擴展。
積極努力通過各種戰略措施應對巴西市場的低迷需求。
Opportunities:
機會：
FDA approval of Motiva implants expected to be a pivotal milestone, enhancing U.S. market entry and global credibility.
Expansion of Mia Femtech in international markets is creating a new category within breast aesthetics, contributing to broad market growth.
預計FDA批准Motiva植入物將是一個關鍵的里程碑，有助於美國市場進軍和全球信譽。
Mia Femtech在國際市場的拓展正在爲乳房美容創造一個新的類別，爲廣泛市場增長做出貢獻。
Risks:
風險：
Ongoing softness in the Brazilian market impacting regional revenue targets.
Potential delays or complications in receiving FDA approval for Motiva implants, specifically related to addressing the FDA's observations during inspections.
巴西市場的持續疲軟影響區域營收目標。
可能會由於解決FDA檢查期間的觀察而導致Motiva植入物的FDA批准出現延遲或複雜情況。
More details: Establishment Labs IR
更多詳細信息：Establishment Labs IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。